SCHEDULE 13G/A: Sphera Funds Management Amends Skye Bioscience Stake to 4.77% Passive Interest

Sphera Funds Management Ltd. and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.77% in Skye Bioscience, Inc.'s common stock as of March 31, 2025.

Summary

• Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP are the reporting persons in this Schedule 13G Amendment No. 1.
• The reporting persons collectively beneficially own 1,476,353 shares of Skye Bioscience, Inc. common stock.
• This ownership represents 4.77% of the total class of common stock outstanding.
• The percentage is calculated based on 30,974,558 shares of common stock issued and outstanding as of March 19, 2025, as reported by Skye Bioscience, Inc. in its Form 10-K filed on March 20, 2025.
• The shares are held through Sphera Global Healthcare Master Fund (266,894 shares, 0.86%) and Sphera Biotech Master Fund, L.P. (1,209,459 shares, 3.90%).
• The investment management authority for these funds is delegated to Sphera Global Healthcare Management LP, which is managed by Sphera Global Healthcare GP Ltd., with Sphera Funds Management Ltd. owning 90% of Sphera Global Healthcare GP Ltd.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in the beneficial ownership percentage below the 5% threshold, which could be interpreted as a slight negative signal regarding institutional confidence, although it is a passive investment disclosure.

Positives

• Sphera Funds Management, a significant institutional investor, continues to hold a substantial passive stake in Skye Bioscience, Inc., indicating ongoing interest in the company.

Negatives

• The beneficial ownership percentage has decreased to 4.77%, which is below the 5% threshold typically requiring an initial Schedule 13G filing, suggesting a reduction in the reporting person's stake from a previous filing.

Risks

• The reduction in Sphera Funds Management's stake below the 5% threshold could signal a potential decrease in institutional confidence or a portfolio rebalancing, which might lead to further divestment.

Future Outlook

The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from the company or the reporting entity regarding future performance or strategy.

Industry Context

This filing reflects a passive investment by a healthcare-focused fund in a biotechnology company. Such filings are routine disclosures of significant ownership stakes and do not inherently indicate broader industry trends, though they confirm continued institutional interest in the sector.

Comparison to Industry Standards

• This is a standard Schedule 13G amendment filing, indicating a passive ownership stake.
• The 4.77% stake is now below the 5% threshold that typically triggers an initial Schedule 13G filing, suggesting a reduction in stake from a previous filing or a re-evaluation of the reporting threshold.
• No specific comparable companies, projects, or results are mentioned within the document to assess the results against industry benchmarks.

Stakeholder Impact

• Shareholders: The reduction in institutional ownership might be perceived negatively, potentially influencing investor sentiment and share price.

Next Steps

• The document is a regulatory filing and does not outline specific future actions or milestones for Skye Bioscience, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Recommendation

Keywords

Skye Bioscience, Sphera Funds Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Equity Stake, Healthcare Investment